Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EmbryoFix Granules is a multi-ingredient nutraceutical supplement developed by MMC Pharmaceuticals, specifically formulated for use in gynecology and fertility management. The product is primarily indicated for improving endometrial thickness and receptivity in women experiencing infertility or recurrent pregnancy loss. Its formulation typically includes L-arginine, lycopene, folic acid, and a complex of essential vitamins (B6, B12) and minerals (Zinc, Selenium). The primary mechanism of action is driven by L-arginine, which serves as a precursor for nitric oxide (NO) production. Nitric oxide acts as a potent vasodilator, enhancing blood flow to the uterus and ovaries, which in turn supports the development of a healthy endometrial lining suitable for embryo implantation. Additionally, antioxidants like lycopene and selenium help mitigate oxidative stress in the reproductive environment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EmbryoFix Granules.